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Abstract
The circadian clock underlies daily rhythms of diverse physiological processes, and alterations in clock function have been
linked to numerous pathologies. To apply chemical biology methods to modulate and dissect the clock mechanism with
new chemical probes, we performed a circadian screen of ,120,000 uncharacterized compounds on human cells containing
a circadian reporter. The analysis identified a small molecule that potently lengthens the circadian period in a dose-
dependent manner. Subsequent analysis showed that the compound also lengthened the period in a variety of cells from
different tissues including the mouse suprachiasmatic nucleus, the central clock controlling behavioral rhythms. Based on
the prominent period lengthening effect, we named the compound longdaysin. Longdaysin was amenable for chemical
modification to perform affinity chromatography coupled with mass spectrometry analysis to identify target proteins.
Combined with siRNA-mediated gene knockdown, we identified the protein kinases CKId, CKIa, and ERK2 as targets of
longdaysin responsible for the observed effect on circadian period. Although individual knockdown of CKId, CKIa, and ERK2
had small period effects, their combinatorial knockdown dramatically lengthened the period similar to longdaysin
treatment. We characterized the role of CKIa in the clock mechanism and found that CKIa-mediated phosphorylation
stimulated degradation of a clock protein PER1, similar to the function of CKId. Longdaysin treatment inhibited PER1
degradation, providing insight into the mechanism of longdaysin-dependent period lengthening. Using larval zebrafish, we
further demonstrated that longdaysin drastically lengthened circadian period in vivo. Taken together, the chemical biology
approach not only revealed CKIa as a clock regulatory kinase but also identified a multiple kinase network conferring
robustness to the clock. Longdaysin provides novel possibilities in manipulating clock function due to its ability to
simultaneously inhibit several key components of this conserved network across species.
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Introduction
A variety of physiological processes such as sleep/wake behavior,
body temperature, hormone secretion, and metabolism show daily
rhythms under the control of the circadian clock which is intrinsic to
the organism. Perturbation of clock function has been implicated in
numerous pathologies including circadian sleep disorders, cardiovas-
cular disease, cancer, and metabolic disease [1–4]. The close
association of the circadian clock with diverse physiological processes
and diseases implies that identification of clock-modulating com-
pounds could form the basis for therapeutic strategies directed towards
circadian rhythm-related disorders, shift-work fatigue, and jet lag.
The manifestation of circadian disorders at the level of the
whole organism can be caused by dysfunction of the clock at the
level of intracellular networks, as single cells exhibit circadian
rhythms in a cell-autonomous manner [5–6]. In mammals, these
cellular oscillators are organized in a hierarchy, in which the
suprachiasmatic nucleus (SCN) of the hypothalamus constitutes
the central circadian pacemaker controlling behavioral rhythms,
while peripheral clocks in other tissues control local rhythmic
outputs [1,3,7]. In the intracellular circadian network, the clock
genes and their protein products form transcriptional feedback
loops: CLOCK and BMAL1 transcription factors activate
expression of Per and Cry genes, and PER and CRY proteins
(PER1, PER2, CRY1, and CRY2) in turn inhibit their own
transcription to generate rhythmic gene expression [3,8].
In addition to transcriptional regulation, post-translational
modification of clock proteins provides another level of regulation,
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Hamster tau mutants showing a short period behavioral rhythm
have a missense mutation in the CKIe gene [10], and human
familial advanced sleep phase syndrome (FASPS) with early sleep
times is attributed to missense mutations of PER2 and CKId genes
[11–12]. CKId and CKIe phosphorylate PER to trigger
proteasomal degradation, and tau and FASPS mutations lead to
higher PER degradation than wild type, consistent with the short
period phenotype [13–15]. Supporting the functional importance
of CKId/e, application of the known CKI inhibitors IC261, CKI-
7, and D4476 causes period lengthening in cultured cells [14,16–
17]. Generation of CKIe and CKId deficient mice [15,18] as well
as the development of the CKIe-selective inhibitor PF-4800567
[19] revealed the minimal, if any, role of CKIe in period length
regulation and also demonstrated a dominant role for CKId.I n
contrast, potential roles of CKI family members other than CKId/
e are less characterized: They show much less binding with PER1
than that of CKIe [20–22], and knockdown of CKIa-like, a
homolog of CKIa, has no period effect in cultured cells [23].
Together with CKId/e, GSK-3b and CK2 are also implicated in
period regulation. GSK-3b phosphorylates PER2, CRY2, REV-
ERBa, CLOCK, and BMAL1 for functional regulation [24–28],
and pharmacological and RNAi-based inhibition of GSK-3b
causes period shortening in cultured cells [29–30]. Conversely,
inhibition of CK2 causes period lengthening [29,31–33], and
CK2-mediated phosphorylation regulates PER2 and BMAL1
functions [31–32,34].
Genetic and molecular biological studies over the past two
decades have identified more than a dozen genes that form the
core of the mammalian circadian network [3,8,35]. However, it is
clear that more clock components and modulators remain to be
discovered [36]. Considering the limitations of conventional
biological approaches associated with lethality, pleiotropy, and
functional redundancy of closely related proteins, introduction of
new strategies will accelerate the identification of novel clock
mechanism. Chemical biology approaches are attractive candi-
dates, because they utilize small molecules as proof-of-concept
probes for biological systems and can be effective in discovering
novel biological mechanisms and evaluating their effects in vivo by
complementing the limitations of conventional biological ap-
proaches [7,37]. Furthermore, the circadian clock network can be
a good target for chemical biology approaches due to the
quantitative readout of an oscillation. To discover new chemical
probes for dissecting biological mechanisms, it is valuable to screen
comprehensive, large-scale compound libraries containing hun-
dreds of thousands of compounds, because a wide variation of
chemical structures has the advantage of probing many classes of
potential targets. Although it is technically challenging to identify
proteins specifically affected by a novel compound [38], this
process might also be necessary for known compounds, given that
even well-characterized kinase inhibitors have off-targets unrelated
to the primary effect [39–40]. Combined with conventional
biological approaches, the chemical biology approach is expected
to provide an effective way to identify novel components of the
circadian clock [41].
We previously developed a cell-based high-throughput circadi-
an assay system to perform compound screening [29]. In this
system, Bmal1-dLuc reporter cells derived from human U2OS
osteosarcoma cells show robust luminescence rhythms on 384-well
plates by expressing a rapidly degradable luciferase under the
control of a mouse Bmal1 gene promoter. We initially tested a
chemical library containing 1,280 well-characterized compounds
(LOPAC; Library of Pharmacologically Active Compounds) and
found 11 compounds that change period length of the lumines-
cence rhythms in a dose-dependent manner. The kinase inhibitors
among the hit compounds revealed novel roles of GSK-3b and
CK2 in the mammalian clock mechanism as described above.
Furthermore, many of the hits were previously known to alter the
circadian period in other organisms and tissue preparations,
demonstrating the predictive value of the high-throughput assay
system [29]. Together, these observations indicate the effectiveness
of small molecules as probes and/or modulators of the circadian
clock mechanism. A similar LOPAC screen in NIH3T3 and
U2OS cells identified CKId/e-dependent phosphorylation as a
chemically sensitive process of the clock [42]. It was found that the
CKId/e-targeting compounds cause much larger period length-
ening than CKId gene knockout [18,29,42], but the molecular
mechanism underlying the strong effects of the compounds
remains unknown. The present study aimed to apply chemical
biology methods to probe the clock mechanism with novel small
molecules through a circadian screen of a structurally diverse
library of ,120,000 uncharacterized compounds. We found a
purine derivative, longdaysin, that dramatically lengthens the
circadian period. Identification and characterization of long-
daysin-target proteins revealed the roles for protein kinases CKIa
and ERK2 in period regulation, as well as confirmed the
importance of CKId. Simultaneous inhibition of these three
kinases drastically lengthened the circadian period, illustrating a
new facet of the clock mechanism whose robustness is conferred in
part by a multiple kinase network.
Results
Identification of a Novel Compound Lengthening the
Circadian Period
By applying a high-throughput circadian assay system using
human U2OS cells with Bmal1-dLuc reporter [29], we analyzed
approximately 120,000 uncharacterized compounds correspond-
ing to diverse chemical scaffolds [43–44] at a final concentration of
7 mM. We identified a number of compounds with different
scaffolds that lengthened the circadian period of cellular
luminescence rhythms. Among them, we selected one purine
derivative compound 1 (Figure 1A) for follow-up studies, because
Author Summary
Most organisms show daily rhythms in physiology,
behavior, and metabolism, which may be advantageous
because they anticipate environmental changes thus
optimize energy metabolism. These rhythms are controlled
by the circadian clock, which produces cyclic expression of
thousands of output genes. More than a dozen compo-
nents of the circadian clock are called clock genes, and the
proteins they encode form a transcription factor network
that generates rhythmic gene expression. In this study, we
set out to control the function of the circadian clock and to
identify new clock proteins by means of chemical tools. We
tested the effects on the clock in human cells of around
120,000 uncharacterized compounds. Here we describe
identification of a novel compound ‘‘longdaysin’’ that
markedly slows the circadian clock both in cultured
mammalian cells and in living zebrafish. By using long-
daysin as a chemical probe, we found new proteins that
modulate clock function. Because defects of clock function
have been linked to numerous diseases, longdaysin may
form the basis for therapeutic strategies directed towards
circadian rhythm-related disorders, shift-work fatigue, and
jet lag.
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showed less effect on the amplitude of Bmal1-dLuc rhythms (Figure
S1). A preliminary structure-activity relationship study helped to
identify a derivative of compound 1 that is 3 times more potent
and able to generate .10 h period change at a concentration of
10 mM (Figure 1B and Table 1). We termed this derivative
‘‘longdaysin’’ (Figure 1A), based on its prominent period
lengthening effect. We further investigated the effect of longdaysin
(Figure 1C–E) by using primary cells and tissues isolated from
mPer2
Luc knockin mice harboring a mPer2
Luc reporter [45–46] as an
additional clock-controlled reporter different from Bmal1-dLuc
used in the screen. Longdaysin consistently caused dose-dependent
period lengthening in adult tail fibroblasts (Figure 1C) and lung
explants (Figure 1D), which represent peripheral clocks, and in
SCN explants (Figure 1E), which represent the central clock. The
effect of longdaysin was reversible, as the period length returned to
normal after washout of the compound (Figure S2). Taken
together, these results demonstrate that longdaysin potently
lengthens the circadian period in multiple mammalian cells
including SCN neurons.
Binding of Longdaysin With Protein Kinases
In order to identify potential biological targets of longdaysin by
affinity-based proteomic approaches [38], we synthesized long-
daysin analogs with an aminohexyl linker, based on the
preliminary structure-activity relationship analysis. Among them,
compound 2 with a linker at the C2 position (Figure 2A) retained
the period lengthening effect in the cell-based circadian assay
(Figure 2B). We then prepared agarose-conjugated compound 3
(Figure 2A) and incubated it with U2OS cell lysate in the presence
or absence of 100 mM longdaysin as a soluble competitor
(Figure 2C). Proteins that bound to the affinity resin, and could
Figure 1. Effect of a novel compound on the circadian period in cultured cells and tissues. (A) The chemical structure of compound 1 and
longdaysin. (B) Effects of compound 1 and longdaysin on the luminescence rhythms in Bmal1-dLuc U2OS cells. Luminescence rhythms were
monitored in the presence of various concentrations of compound (10 points of 3-fold dilution series in DMSO; final 0.7% DMSO). The representative
luminescence profiles for longdaysin treatment are indicated as raster plot (left panel), in which each horizontal raster line represents a single well,
with elapsed time plotted to the right. Luminescence intensity is indicated by color scale. Period parameter was obtained by curve fitting, and period
change relative to the mean of DMSO control was plotted against compound concentration (right panel; the mean with SEM, n=4). Longdaysin
showed cytotoxicity at 71 mM. (C–E) Effect of longdaysin on the circadian period in adult tail fibroblasts (C), lung explants (D), and SCN explants
(E) from mPer2
Luc knockin mice. Fibroblasts were cultured in the presence of various concentrations of longdaysin (the mean with SEM, n=4). Lung
and SCN explants were cultured in the presence of increasing concentration of longdaysin (0 to 9 mM; 1 wk for each concentration), and period
change relative to the mean of DMSO control at first week was plotted for individual culture (n=3 for lung and n=2 for SCN).
doi:10.1371/journal.pbio.1000559.g001
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and analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS). This analysis yielded 10 proteins (Figure 2D)
includingtheprotein kinases(highlighted inblue)CKId(CSNK1D),
CKIa (CSNK1A1), ERK2 (MAPK1), CDK7, and p38a
(MAPK14). Independent affinity chromatography followed by
Western blotting with specific antibodies confirmed both the
binding of the protein kinases to the affinity resin as well as
decreased binding in the presence of free longdaysin (Figure S3).
Furthermore, in vitro kinase assays revealed that longdaysin
inhibited CKId, CKIa, ERK2, and CDK7 activities (IC50=8.8,
5.6, 52, and 29 mM, respectively; Figure 2E and Table 1), while it
had much less effect on p38a (unpublished data). In contrast,
compound 1 inhibited CKId,C K I a, and ERK2 with ,3 times less
potency than longdaysin and inhibited CDK7 similarly to long-
daysin (Figure 2E and Table 1). The difference in potency between
longdaysin and compound 1 against CKId, CKIa, and ERK2 was
consistent with their cellular period effects (Table 1), suggesting an
involvement of these three kinases in the period regulation.
Lengthening of the Circadian Period by Knockdown of
CKId, CKIa, and ERK2
To identify the protein(s) mediating longdaysin effect on period
length, we first tested the contribution of CKId, a well-
characterized kinase in period regulation [12,18–19,47], by using
embryonic fibroblasts prepared from CKId deficient mice
harboring the mPer2
Luc knockin reporter [18]. In a 384-well plate
format, the period of CKId deficient (CKId
D2/D2) cells was 1.1 h
longer than that of wild type (CKId
+/+) cells (CKId
D2/D2,
25.960.5 h; CKId
+/+, 24.860.9 h; n=48), consistent with a
previous report [18]. We found that longdaysin lengthened the
period in a dose-dependent manner in CKId deficient cells as well
as in wild type cells (Figure 3A). This result indicates the presence
of additional longdaysin-target(s) that regulate period length
besides CKId.
To investigate the effects of RNAi-mediated inhibition of
potential longdaysin-targeted kinases on the circadian period, we
conducted knockdown experiments by applying four independent
siRNAs against each gene. At least two siRNAs for CSNK1D
(encoding CKId), CSNK1A1 (CKIa), and MAPK1 (ERK2) caused
period lengthening (Figure 3B, red box), while those for CDK7 and
MAPK14 (p38a) did not, thus proposing CKId, CKIa, and ERK2
as the potential clock-acting targets of longdaysin. We also tested
siRNAs against the close homologs of these three kinases (CSNK1E
for CSNK1D, CSNK1A1L for CSNK1A1, and MAPK3 for MAPK1)
and found that the homologs had little or no effect on the period
(Figure 3B). The minor period effects for MAPK14, CSNK1E, and
CSNK1A1L are in line with previous reports [23,42]. We further
looked at the primary screening data from our genome-wide RNAi
study [33] in which we used four siRNAs different from this study
by combining two siRNAs as a pool. Among the 10 longdaysin-
interacting proteins identified by the affinity chromatography
(Figure 2D), only CSNK1D, CSNK1A1, and MAPK1 showed period
lengthening of the reporter with both siRNA pairs (Figure S4, red
box), supporting important roles for CKId, CKIa, and ERK2 in
period regulation as longdaysin targets. We then characterized the
period lengthening effects of siRNAs against CSNK1D, CSNK1A1,
and MAPK1 by using an 8-point dilution series of the effective
siRNAs. All siRNAs tested gave dose-dependent changes of the
period (Figure 3Ci) and reduction of the target gene mRNA levels
without affecting the levels of closely homologous genes
(Figure 3Cii). The only exception was CSNK1A1 si1, which has
sequence similarity against CSNK1A1L mRNA (96% identical on a
23 bp stretch) and reduced its level at higher dose (Figure 3Cii).
The correlation between period effect and mRNA knockdown
effect matched well for two siRNAs against CSNK1A1 or MAPK1
(Figure S5). The proportional changes of circadian function by
dose-dependent knockdown of CSNK1D, CSNK1A1, and MAPK1
(Figure 3C) are common characteristics among the core clock
components and clock modifiers [23,33]. Taken together, these
results illustrate the involvement of CKIa and ERK2 in the period
regulation, as well as confirming the importance of CKId.
We further tested knockdown of all three kinases CSNK1D,
CSNK1A1, and MAPK1 in combination, in order to determine if
their concomitant reduction could explain the strong effect of
longdaysin as an inhibitor of all three kinases. Combinatorial
knockdown of the three genes caused strong and dose-dependent
lengthening of the period to .10 h (Figure 3Di). The multiple
gene knockdown effect (Figure 3Dii, red line) matched well with
the theoretical sum of the effect of single gene knockdown (black
line). These results suggest that the knockdown of these three
kinases works in an additive manner to cause prominent period
lengthening similar to that generated by longdaysin.
CKIa-Dependent Phosphorylation and Degradation of
PER1
In contrast to the well-characterized roles of CKId/e-mediated
phosphorylation of PER proteins [9–21], the functions of CKIa
and ERK2 in period regulation have yet to be characterized. To
examine the interaction of CKIa and ERK2 with the core clock
proteins, we co-expressed HA-tagged kinases with Flag-tagged
clock proteins in HEK293T cells. Immunoprecipitation assay
revealed interactions of both CKIa and ERK2 with PER1 and
PER2, and to a lesser extent, CRY1 and CRY2 (Figures 4A, S6A,
Table 1. Effective concentrations of longdaysin and compound 1.
U2OS Cell-Based Circadian Assay
(Concentrations for Period Change,
mM)
a In Vitro Kinase Assay (IC50, mM)
b
Cell-Based PER1
Degradation Assay (EC50,
mM)
c
Compound 5 h 10 h 15 h CKId CKIa ERK2 CDK7 CKId CKIa
Longdaysin 1.5 5.7 13 8.8 5.6 52 29 9.7 9.2
Compound 1 4.4 17 38 21 23 160 29 n.d. n.d.
a–cValues were determined from
aFigure 1B,
bFigure 2E, and
cFigure 4E.
n.d., not determined.
doi:10.1371/journal.pbio.1000559.t001
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electrophoretic mobility forms of PER1 (Figure 4B), which
disappeared upon phosphatase treatment (Figure S7A), suggesting
CKIa-dependent phosphorylation of PER1. This modification
relied on the kinase activity of CKIa, because the kinase-dead
K46R mutant of CKIa [CKIa (KR)] [48] did not cause the
mobility-shift of PER1 (Figure 4B). In contrast, ERK2 showed no
detectable effect on the PER1 mobility (unpublished data).
Treatment of the cells with longdaysin reduced the CKIa- and
CKId-dependent mobility-shift of PER1 (Figures 4C, S7B, and
S7C), consistent with a potential mode of longdaysin action
through CKIa and CKId.
Figure 2. Identification of potential longdaysin-binding proteins. (A) The chemical structure of compounds 2 and 3. A circle represents an
agarose bead. (B) Effect of compound 2 on the circadian period. Luminescence rhythms of Bmal1-dLuc U2OS cells were monitored in the presence of
various concentrations of compound 2. Data are the mean with SEM (n=4). (C) The scheme of longdaysin-binding protein identification. Cell lysate
was prepared from confluent and unsynchronized U2OS cells. (D) A list of potential longdaysin-binding proteins. Listed proteins were identified by
$10 tandem MS spectra and showed $3-fold signal reduction upon competition with free longdaysin. Protein kinases are highlighted in blue.
Sequence coverage refers to the experiment performed in the absence of free longdaysin [competition (2)]. (E) Effects of longdaysin and compound
1 on protein kinase activity. Activities of CKId, CKIa, ERK2, and CDK7 in vitro were analyzed in the presence of various concentrations of compound.
Data are the mean with SEM (n=6 for longdaysin, n=4 for compound 1).
doi:10.1371/journal.pbio.1000559.g002
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from CKId deficient mPer2
Luc knockin mice. Luminescence rhythms of CKId deficient (CKId
D2/D2) or wild type (CKId
+/+) cells were monitored in the
presence of various concentrations of longdaysin. Period change relative to the mean of DMSO control of wild type cells was plotted (the mean with
SEM, n=4). (B) Effects of kinase gene siRNAs on the circadian period in Bmal1-dLuc U2OS cells. Luminescence rhythms were monitored after transient
transfection with siRNA. Period parameter was obtained by curve fitting, and period change relative to the mean of control was plotted. Data are the
mean with variation (n=2). The period estimation for CSNK1D si4 was not accurate because of poor curve fitting (indicated by asterisk). (C) Dose-
dependent effects of kinase gene siRNAs on the circadian period (Ci) and the gene expression (Cii). Luminescence rhythms of Bmal1-dLuc U2OS cells
were monitored after transient transfection with various amounts of siRNA (Ci). Representative profiles are indicated in the left panels, and period
changes were plotted against siRNA amount in the right panels (the mean with SEM, n=5–6). Gene expression of unsynchronized cells at time 0 h
was analyzed by RT-qPCR (Cii). Expression levels of target gene, homologous gene, and control gene (ACTB) are indicated in the left, middle, and right
panels, respectively, by setting control value as 1. Data are the mean with variation (n=2). (Di) Effect of multiple kinase gene knockdown on the
circadian period. Equal amounts of CSNK1D si3, CSNK1A1 si4, MAPK1 si4, and control siRNA were mixed and used for transient transfection. Data are
the mean with SEM (n=8). (Dii) Comparison of single and multiple kinase gene knockdown effects. Effects of single (pink, blue, and purple lines; data
from Ci) and multiple (red line; data from Di) gene knockdown were plotted against each siRNA amount. Black line is the theoretical sum of single
gene knockdown effects.
doi:10.1371/journal.pbio.1000559.g003
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PLoS Biology | www.plosbiology.org 6 December 2010 | Volume 8 | Issue 12 | e1000559Figure 4. Effect of CKIa on the core clock proteins. (A) Interaction of CKIa and ERK2 with the core clock proteins. HA-tagged CKIa or ERK2 was
co-expressed with Flag-tagged clock proteins in HEK293T cells and subjected to immunoprecipitation assay with anti-HA antibody. Because of the
low level expression CLOCK, its interaction could not be tested. The interaction of ERK2 with CRY1 and CRY2 was detected as reported previously [67].
(B) CKIa-dependent phosphorylation of PER1. PER1 was co-expressed with CKIa, kinase-dead mutant of CKIa [CKIa (KR)], or CKId in HEK293T cells and
analyzed by Western blot 2 d after transfection (left panel). Intensity profile of each PER1 band is shown in right panel by setting the peak value as 1.
Bracket indicates lower electrophoretic mobility forms of PER1 whose intensity increased in the presence of CKIa or CKId. (C) Effect of longdaysin on
CKIa- and CKId-dependent phosphorylation of PER1. PER1 was co-expressed with CKIa or CKId in HEK293T cells. The cells were treated with 10 mM
longdaysin or 0.1% DMSO for 24 h, and a part of the cell extract was analyzed by Western blot. (D) Effect of CKIa on PER1 stability. Luciferase-fused
A New Small Molecule Modulator of Circadian Clock
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we further tested the effect of CKIa on the stability of PER1 by
expressing luciferase-fused PER1 protein (PER1-LUC) in
HEK293T cells. Luminescence changes were monitored following
inhibition of de novo protein synthesis by cycloheximide treatment.
Co-expression of CKIa but not CKIa (KR) accelerated PER1-
LUC degradation relative to that of LUC (Figure 4D). The CKIa-
and CKId-dependent degradation of PER1 was inhibited by
longdaysin treatment in a dose-dependent manner (Figure 4E).
Similar results were obtained by using PER1 without the LUC
fusion (Figure S8A). In contrast, we found that CKIa had no effect
on the stability of a PER2-LUC fusion protein while CKId
accelerated its degradation (Figure S8B). These results demon-
strated the selectivity of CKIa against PER1 degradation over
PER2. Longdaysin inhibited the CKId-mediated PER2-LUC
degradation in a dose-dependent manner (Figure S8C), suggesting
its role in regulating both PER1 and PER2 stabilities through
CKId and/or CKIa.
We then investigated the effect of longdaysin on the protein
level of endogenous PER1 in Bmal1-dLuc U2OS cells during
circadian cycles. The cells were synchronized with medium change
and collected every 6 h from 28 h to 58 h after the medium
change (Figure 4Fi). Consistent with the longdaysin-dependent
shift of the second trough of Bmal1-dLuc luminescence rhythm (34,
38, and 46 h for 0, 3, and 9 mM longdaysin, respectively;
Figure 4Fi), the second peak of PER1 protein rhythm shifted in
parallel (40, 40–46, and 52 h for 0, 3, and 9 mM longdaysin,
respectively; Figure 4Fii). Furthermore, 3 or 9 mM longdaysin
treatment strongly up-regulated overall protein amount of PER1
compared with 0 mM control (Figure 4Fii) without affecting its
mRNA level (Figure 4Fiii), demonstrating post-transcriptional
increase of endogenous PER1 by longdaysin. The progressive
phosphorylation of PER1 was still observed in the presence of
longdaysin (Figure 4Fii), possibly because of the phosphorylation
by kinase(s) that was not affected by longdaysin. Collectively, these
results provide a possible mechanism of longdaysin action for
period regulation through the CKIa- and CKId-mediated control
of PER1 stability.
Period Lengthening of Gene Expression Rhythms by
Longdaysin in Zebrafish In Vivo
Lastly, we investigated if longdaysin had any in vivo efficacy by
using zebrafish, which provide a useful model system for studies on
circadian rhythms at the level of the whole organism [49], and
have conserved CKI and ERK family genes [50–51]. By using
transgenic zebrafish harboring a per3-luc reporter [52], we first
established an in vivo circadian assay to investigate the effects of
compounds. Larval per3-luc fish were entrained in 12 h light/12 h
dark cycles from day 3 to 6 postfertilization and then placed in an
individual well of a 96-well plate to monitor luminescence rhythms
under constant darkness. By using this assay, we found that
longdaysin treatment caused .10 h period lengthening in a dose-
dependent manner in per3-luc reporter fish (Figure 5A and 5B),
without affecting body size (Figures 5C and S9). The in vivo period
changes were similar to those observed in mammalian tissues and
cells (Figure 1), showing the prominent characteristics of long-
daysin as a period lengthening compound.
Discussion
The present study highlighted the effectiveness of the chemical
biology approach in dissecting circadian clock mechanisms. Our
large-scale small molecule screening identified a novel compound
longdaysin that exhibited a drastic effect on the circadian period of
not only a variety of mammalian cells but also zebrafish in vivo. As
a first attempt to determine the molecular mechanism underlying
such a large period effect, we conducted affinity-based proteomics
and siRNA-mediated knockdown analyses. Our results revealed
CKId, CKIa, and ERK2 as targets of longdaysin for period
regulation. Effective concentrations of longdaysin against CKId
and CKIa in a cell-based PER1 degradation assay were similar to
those in in vitro kinase assays (Table 1), suggesting efficient cell
permeability of the compound. Treatment with 10 mM longdaysin
consistently inhibited CKId and CKIa activities in vitro and their
effects on PER1 phosphorylation and degradation, resulting in a
13 h period lengthening in U2OS cells. The increasing period
effect at the range of 3 to 24 mM, in which longdaysin considerably
inhibited ERK2 in vitro, supported the role of ERK2 at higher
longdaysin concentration.
In mammals, the CKI family of Ser/Thr kinases contains seven
members (a, b, c1, c2, c3, d, and e). While the roles of CKId/e in
the circadian clock mechanism have been extensively studied, the
inhibition of CKId/e alone is insufficient to explain the drastic
effect of longdaysin. Knockout of these genes has only a modest
effect on period length and the effect of longdaysin was also
observed in CKId deficient cells. We found that CKIa, in addition
to CKId and CKIe, binds to PER1 and regulates its stability. This
observation is reminiscent of the CKIa-, CKId-, and CKIe-
mediated regulation of b-catenin and Ci, key players in the Wnt
and Hedgehog signaling pathways [53–54]. Similar to NFAT
transcription factors that are the targets of CKIa and/or CKIe
[55–56], the CKI docking site of PER1/2 contains a FXXXF
motif necessary for CKIe binding [56]. Although PER1/2 bind
with CKIa/d/e, the affinity of CKIa is much lower than CKId/e
(Figure S6C). A recent study demonstrated that two amino acid
residues in the CKI kinase domain cause weaker affinity of CKIa
for PER1 compared with CKIe [22]. The low affinity will be
advantageous to release PER proteins from CKIa for subsequent
regulations, such as phosphorylation by other kinases and
degradation. Disruption of the circadian rhythm in CKId deficient
fibroblasts by overexpression of dominant negative form of CKIe
[57] may be mediated also by perturbation of CKIa-dependent
regulation, because of the tight binding of dominant negative
CKIe with PER proteins. On the other hand, ERK1 and ERK2
PER1 (PER1-LUC) or luciferase (LUC) was co-expressed with GFP, CKIa, CKIa (KR), or CKId in HEK293T cells. The cells were treated with cycloheximide
from time 0, and luminescence was recorded. Representative profiles for PER1-LUC and LUC are shown in the left and middle panels, respectively, by
setting peak luminescence as 100%. Half-life of PER1-LUC was divided by that of LUC to cancel out the effect of LUC degradation on PER1-LUC
stability (right panel). Data are the mean with SEM (n=4). (E) Effect of longdaysin on CKIa- and CKId-dependent regulation of PER1 stability. PER1-LUC
or LUC was co-expressed with GFP, CKIa, or CKId in HEK293T cells. The cells were treated with 0 to 20 mM longdaysin for 24 h and then treated with
cycloheximide for luminescence recording. Representative profiles for PER1-LUC and LUC are shown in the left and middle panels, respectively. The
relative half-life of PER1-LUC against LUC is indicated (right panel). Data are the mean with SEM (n=6). (F) Effect of longdaysin on endogenous PER1
level in Bmal1-dLuc U2OS cells. Luminescence rhythms were monitored in the presence of 0, 3, or 9 mM longdaysin (Fi). In parallel, the cells were
collected at indicated time points and analyzed by Western blotting (Fii). Also, the cells were collected at two time points separated by about half of
the period length (40 and 52 h for 0 mM longdaysin, 40 and 55 h for 3 mM, 40 and 58 h for 9 mM) and analyzed by RT-qPCR as a mixture of the two
time points (Fiii, the mean with SEM, n=4).
doi:10.1371/journal.pbio.1000559.g004
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mechanism of the clock [58]. Our results demonstrated a role
for ERK2 in the regulation of circadian period as well.
Attenuation of the circadian rhythms in SCN explants by
treatment with the MEK (ERK kinase) inhibitor U0126 [59]
could potentially be explained by strong inhibition of both ERK1
and ERK2. Similar to CKId and CKIa, ERK2 bound to PER1/
2, suggesting PER protein as a key node in phosphorylation-
dependent period regulation by multiple kinases. The effect of
ERK2 on PER phosphorylation and function will be addressed in
future studies.
CKId, CKIa, and ERK2 are involved in diverse cellular
processes such as cell proliferation and apoptosis [53,60].
Consistently, CKId and ERK2 are required for normal develop-
ment as revealed by gene knockout studies [18,61–62], while
CKIa deficient mice are not reported yet. In addition to the
regulation of PER by these kinases, it is possible that the regulation
of other clock proteins and/or changes in cellular physiology may
also affect the circadian period. Therefore, it is important to
identify specific residues of PER responsible for the CKId-, CKIa-,
and ERK2-mediated period regulation. In contrast to the CKId-
dependent progressive phosphorylation of PER1, CKIa caused a
smaller mobility-shift (Figure 4B,C), suggesting a key role for site-
specific phosphorylation rather than a global change of phosphor-
ylation level. In Neurospora, a quantitative mass spectrometry
approach identified .75 in vivo phosphorylated residues of the
clock protein FRQ [63]. Interestingly, phosphorylation of two
distinct regions leads to opposing effects on FRQ stability and
circadian period [63]. In mammals, phosphorylation site mapping
via mass spectrometry identified 21 phosphorylated Ser/Thr
residues in PER2 overexpressed in HEK293 cells [14]. Identifi-
cation of PER1 phosphorylation sites and characterization of the
role of each residue will lead to the understanding of CKId-,
CKIa-, and ERK2-mediated regulation of PER1 function and the
circadian period. Furthermore, the phenotypic differences be-
tween PER1 and PER2 observed in CKIa-dependent regulation
of stability (Figure S8B) and CKIe-mediated control of nuclear
translocation [64] could be explained by comparing phosphory-
lation sites and their functions.
We found that combinatorial knockdown of CKId, CKIa, and
ERK2 worked additively for prominent period lengthening
(Figure 3D), similar to that caused by longdaysin. In contrast,
knockout of CKId (Figure 3A), knockdown of single kinase
(Figure 3B,C), and CKI inhibitors D4476 and IC261(Figure S10)
all showed smaller period effects. These observations indicate that
the network of multiple kinases confers robustness to the clock
mechanism. A single small molecule such as longdaysin inhibiting
the multiple pathways simultaneously can significantly perturb the
clock system and elicit unexpectedly long period. Previous
screening of the LOPAC chemical library identified several kinase
inhibitors that cause large period lengthening [29,42]. These
compounds have the potential to inhibit CKId/e [39–40,42],
although their primary target is CDK, p38 MAPK, JNK, CK2, or
VEGFR signaling pathway. Because of the high conservation of
the kinase domain between CKId and CKIa, these compounds
are also likely to inhibit CKIa. Considering our current finding,
Figure 5. Effect of longdaysin on the circadian period in zebrafish in vivo. Zebrafish hemizygous for per3-luc were entrained in 12 h light/
12 h dark cycles, and then luminescence rhythms were monitored in constant darkness in the presence of various concentrations of longdaysin.
Representative luminescence rhythm of individual fish (n=5 for each condition) was plotted after smoothing with 2.4 h moving average and baseline
subtraction with fourth order polynomial curve (A). Period parameter was obtained by curve fitting and plotted against compound concentration (B)
(n=13, 5, 11, and 8 for 0, 1, 3, and 9 mM longdaysin, respectively). Representative pictures of zebrafish after 1 wk of treatment with longdaysin are
shown (C). Scale bar, 1 mm.
doi:10.1371/journal.pbio.1000559.g005
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CK2, or VEGFR signaling pathway) in combination with CKId/
e/a may be essential for the large period effect of these
compounds. Supporting this idea, CK2 acts cooperatively with
CKIe to regulate PER2 stability [32]. Having multiple targets
might be a common characteristic of therapeutically effective
compounds, such as sunitinib and sorafenib for cancer treatment
[65]. Our zebrafish experiments clearly showed an in vivo effect of
longdaysin in a vertebrate, and further optimization of longdaysin
in mammalian systems may provide a chemical starting point for
the identification of small molecule therapeutics specifically
designed for ameliorating circadian disorders.
Materials and Methods
Ethics Statement
All animal studies were approved by the University of
California, San Diego, Institutional Animal Care and Use
Committee and performed in accordance with the guidelines.
Compounds
Synthesis of compound 1, longdaysin, compound 2, and
compound 3 is described in Text S1. The dilution series of the
compounds was made on 384-well plates by using a robotic liquid
handling system (MiniTrak, Perkin-Elmer).
Cell-Based Circadian Assay for Compound Experiment
The compound screen was done with the high-throughput
circadian assay system as described previously [29]. In brief,
Bmal1-dLuc U2OS cells were suspended in the culture medium
(DMEM supplemented with 10% fetal bovine serum, 0.29 mg/ml
L-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomy-
cin) and plated onto 384-well white solid-bottom plates at 20 ml
(2,000 cells) per well. After 2 d, 50 ml of the explant medium
(DMEM supplemented with 2% B27, 10 mM HEPES, 0.38 mg/
ml sodium bicarbonate, 0.29 mg/ml L-glutamine, 100 units/ml
penicillin, 100 mg/ml streptomycin, 0.1 mg/ml gentamicin, and
1 mM luciferin, pH 7.2) was dispensed to each well, followed by
the application of 500 nl of compounds (dissolved in DMSO; final
0.7% DMSO). The plate was covered with an optically clear film
and set to luminescence monitoring system equipped with a CCD
imager (ViewLux, Perkin Elmer). The luminescence was recorded
every 2 h for 3–4 days. In follow-up studies, the luminescence was
recorded every 100 min by using a microplate reader (Infinite
M200, Tecan). The period parameter was obtained from the
luminescence rhythm by curve fitting program CellulaRhythm
[29] or MultiCycle (Actimetrics), both of which gave similar
results.
Luminescence rhythms of adult tail fibroblasts [46] and
embryonic fibroblasts [18] from mPer2
Luc knockin mice were
analyzed similarly to U2OS cells, except that 1,800 cells were
plated per well. Because of the low luminescence intensity of the
fibroblasts, the higher sensitivity ViewLux imager was used for
rhythm recording.
Explant Culture of Mouse Tissues
Explants of lung and SCN were dissected from mPer2
Luc knockin
mice [45] and cultured in explant medium as described previously
[46]. The medium was changed every week with increasing
concentration of longdaysin each time (from 0 to 9 mM, final 0.7%
DMSO). The luminescence was recorded every 10 min with
LumiCycle luminometer (Actimetrics), and the period parameter
was obtained by using LumiCycle Analysis software (Actimetrics).
Affinity Chromatography
U2OS cells kept in confluence (2610
8 cells) were collected with
ice-cold PBS and homogenized by using Dounce homogenizer in
5 ml of lysis buffer (25 mM MOPS, 15 mM EGTA, 15 mM
MgCl2, 1 mM DTT, 60 mM b-glycerophosphate, 15 mM p-
nitrophenyl phosphate, 1 mM Na3VO4, 1 mM NaF, 1 mM
phenyl phosphate, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
10 mg/ml soybean trypsin inhibitor, 100 mM benzamidine,
pH7.2). The homogenate was sonicated and centrifuged
(16,0006g) at 4uC for 20 min. The resulting supernatant was
split into two, and each portion was incubated with or without
100 mM longdaysin (final 0.1% DMSO) at 4uC for 10 min
(Figure 2C). Then, 120 ml of compound 3 [50% slurry in bead
buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA,
0.1% NP-40, 5 mM NaF, 10 mg/ml leupeptin, 10 mg/ml
aprotinin, 10 mg/ml soybean trypsin inhibitor, 100 mM benzami-
dine, pH 7.4)] was added to the mixture and incubated at 4uC for
1 h with rotation. The agarose beads were washed 6 times with
2 ml of the bead buffer. The bound proteins were eluted with SDS
sample buffer and separated by SDS-PAGE (4%–12% gradient
gel, Invitrogen). The gel was CBB stained, and the gel lane for
each condition was cut horizontally into 24 pieces.
Protein Mass Spectrometry
All gel bands were subjected to LC-MS/MS analysis as described
previously [66]. Tandem MS data were analyzed using Sequest
(ThermoFinnigan,San Jose, CA;Version 3.0). Sequest was setup to
search a Homo sapiens subset of the EBI-IPI database (Version 3.32)
to which a reversed copy of the protein database was appended,
assuming the digestion enzyme trypsin. Sequest was searched with a
fragment ion mass tolerance of 0 Da and a parent ion tolerance of
3.0 Da. Iodoacetamide derivative of cysteine was specified in
Sequest as a fixed modification. Oxidation of methionine was
specified in Sequest as a variable modification.
Scaffold (version Scaffold_2_05_00, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based peptide and
protein identifications. Peptide identifications were accepted if they
could be established at greater than 95.0% probability as specified by
the Peptide Prophet algorithm. Protein identifications were accepted
if they could be established at greater than 99.0% probability and
contained at least three unique peptides. Protein probabilities were
assigned by the Protein Prophet algorithm. Crude differential
quantitation of proteins identified in both pulldown experiments
was performed by comparing the number of assigned peptides.
In Vitro Kinase Assay
The CKId, CKIa, CDK7, and ERK2 kinase assays were
performed on 384-well plates (10 ml volume). The reaction
mixture was as follows: for CKId, 2 ng/ml CKId (Millipore, 14-
520), 50 mM peptide substrate RKKKAEpSVASLTSQCSYSS
corresponding to human PER2 Lys659-Ser674 [47], and CKI
buffer (40 mM Tris, 10 mM MgCl2, 0.5 mM DTT, 0.1 mg/ml
BSA, pH 7.5); for CKIa, 1 ng/ml CKIa (Invitrogen, PV3850),
50 mM CKI peptide substrate (Anaspec, 60547-1), and CKI
buffer; for CDK7, 5 ng/ml CDK7 (Millipore, 14-476), 100 mM
Cdk7/9 peptide substrate (Millipore, 12-526), and CKI buffer; for
ERK2, 1.5 ng/ml ERK2 (Millipore, 14-550), 0.8 mg/ml MBP
(Millipore, 13-104), and ERK buffer (50 mM Tris, 10 mM MgCl2,
0.5 mM DTT, 1 mM EGTA, pH 7.5). Five hundred nl of
compound was added to the mixture (final 5% DMSO), and the
reaction was started by adding ATP (final 5 mM). After incubation
at 30uC for 3h, 10 ml of Kinase-Glo Luminescent Kinase Assay
reagent (Promega) was added, and the luminescence was detected
to determine remaining ATP amount. All of the tested compounds
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by using Prism software (GraphPad Software).
Cell-Based Circadian Assay for RNAi Experiment
siRNAs against protein kinase genes (obtained from Human
Protein Kinome Set, Integrated DNA Technologies) were tested on
384-well plates in Figure 3B, and resynthesized siRNAs (Table S1,
Integrated DNA Technologies) were tested on 96-well plates in
Figure 3C,D by using Bmal1-dLuc U2OS cells as described
previously [29,33]. In brief, for 96-well plates, the siRNA was
spotted onto white solid-bottom plates, and 60 ml of Opti-MEM
(Invitrogen) containing 0.4 ml of Lipofectamine 2000 (Invitrogen)
wasdispensed onto eachwell. Afterincubationatroom temperature
for 20 min, 60 ml of the cells in DMEM supplemented with 20%
fetal bovine serum was dispensed (6,000 cells/well). The cells were
cultured overnight, and the medium was changed to 180 ml of the
culture medium. After 2 d, the medium was changed to 180 mlo f
the explant medium, and the plate was covered with optically clear
film. The luminescence was recorded every 36 min by using the
Tecan luminometer. The period parameter was obtained from the
luminescence rhythm by using MultiCycle software.
RT-qPCR
Bmal1-dLuc U2OS cells were transfected with siRNAs as
described above and harvested just before the change to the
explant medium (i.e., the cells were unsynchronized at the time of
harvest). Total RNA preparation and RT-qPCR were performed
as described previously [29,33]. The primers for qPCR are listed
in Table S2.
Transient Transfection and Immunoprecipitation
HEK293T cells (1.25610
6 cells) were reverse transfected on 6-
well plates by Lipofectamine 2000 with 1 mg each of expression
vectors for C-terminally 3XFlag-tagged clock protein (in
p3XFLAG-CMV-14, Sigma) and N-terminally HA-tagged kinase
(in p3XFLAG-CMV-14). For ERK2, 0.05 mg of expression vector
with 0.95 mg of empty vector was used because of its efficient
expression. After 24 h, the cells were collected with ice-cold PBS
and suspended in 100 ml of incubation buffer [50 mM Tris,
50 mM NaCl, 2 mM EDTA, 10% glycerol, 1 mM DTT,
Complete Protease Inhibitor Cocktail (Roche), Phosphatase
Inhibitor Cocktail 1 and 2 (Sigma), pH 8.0]. The mixture was
supplemented with NP-40 (final 1%) and incubated on ice for
15 min, followed by centrifugation (16,0006g) at 4uC for 10 min.
A part of the resulting supernatant (40 ml) was incubated with
0.4 mg of anti-HA antibody (Roche, 11867423001) cross-linked
with Dynabeads Protein G (Invitrogen) at 4uC for 2 h with
rotation. The beads were washed twice with the incubation buffer
supplemented with 1% NP-40. The bound proteins were eluted
with SDS sample buffer, separated by SDS-PAGE (4%–12%
gradient gel), and analyzed by Western blotting with anti-Flag
antibody (Sigma, F1804) or anti-HA antibody conjugated with
HRP (Roche, 12013819001). For the analysis of PER1 electro-
phoretic mobility-shift, the cell extracts were separated by SDS-
PAGE (3%–8% gradient gel, Invitrogen) and analyzed by Western
blotting with anti-Flag antibody or anti-a-tubulin antibody (Santa
Cruz Biotechnology, sc-32293). Protein concentration of each
sample was measured by the Lowry method using DC protein
assay (BioRad).
Protein Degradation Assay
HEK293T cells (6.0610
4 cells) were reverse transfected on 96-
well white solid-bottom plates by Lipofectamine 2000 with 40 ng
each of expression vectors for C-terminally luciferase-fused PER1
(in p3XFLAG-CMV-14) and N-terminally HA-tagged kinase (in
p3XFLAG-CMV-14). For luciferase (in p3XFLAG-CMV-14),
2 ng of expression vector with 38 ng of empty vector was used
because of its efficient expression. After 48 h, the medium was
supplemented with luciferin (final 1 mM) and HEPES-NaOH
(pH 7.2; final 10 mM). After 1 h, cycloheximide (final 20 mg/ml)
was added to the medium, and the plate was covered with optically
clear film. The luminescence was recorded every 10 min by using
the Tecan luminometer. Half-life was obtained by using Prism
software (GraphPad Software).
Time-Course Assay of Endogenous PER1 Abundance
Bmal1-dLuc U2OS cells were plated onto 6-well-plates (2.0610
5
cells/well). After 2 d, the medium was replaced with 2 ml explant
medium containing 0, 3, or 9 mM longdaysin. The plate was
covered with film and kept at 36uC. At indicated time points, the
cells were collected with ice-cold PBS and stored at 280uC. Then
the cell pellets were homogenized in SDS sample buffer and
analyzed by Western blotting with anti-PER1 antibody (Cosmo
Bio, KAL-KI044) or anti-a-tubulin antibody. In parallel, lumi-
nescence rhythms of the cells plated on 35 mm dishes were
recorded with LumiCycle luminometer at 36uC.
In Vivo Measurement of Luminescence Rhythms in
Zebrafish
The per3-luc transgenic line [52] was obtained from Zebrafish
International Resource Center. Hemizygote larval fish were
entrained in 12 h light/12 h dark cycles from day 3 to 6
postfertilization. They were then placed in an individual well of
a 96-well white solid-bottom plate with 180 ml of E3 solution
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM
MgSO4, pH 7.0) containing 0.5 mM luciferin, 0.013% Amquel
Plus Instant Water Detoxifier (Kordon brand; Novalek, Hayward,
California, United States), and various concentrations of long-
daysin (final 0.1% DMSO). The plate was covered with optically
clear film, and the luminescence was recorded every 36 min by
using the Tecan luminometer at 25uC. The period parameter was
obtained from the luminescence rhythm by using MultiCycle
software.
Supporting Information
Figure S1 Effect of compound 1 on the luminescence
rhythms in Bmal1-dLuc U2OS cells. Luminescence rhythms
were monitored in the presence of various concentrations of
compound 1. The representative profiles are indicated as raster
plot (left panel), in which each horizontal raster line represents a
single well, with elapsed time plotted to the right. Luminescence
intensity is indicated by color scale. Period parameter was
obtained by curve fitting, and period change relative to the mean
of DMSO control was plotted against compound concentration
(right panel; the mean with SEM, n=4).
Found at: doi:10.1371/journal.pbio.1000559.s001 (0.26 MB PDF)
Figure S2 Effect of washout of longdaysin on the
circadian period in cultured cells and tissues. Bmal1-dLuc
U2OS cells (left panel) were cultured in the presence of various
concentrations of longdaysin for 5 d (pre-wash). Then the medium
was replaced, and the cells were cultured without longdaysin for
another 5 d (post-wash). Period change relative to the mean of pre-
wash 0 mM condition was plotted for individual culture (n=5 for
each condition). Adult tail fibroblasts (middle panel) and lung
explants (right panel) from mPer2
Luc knockin mice were treated
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respectively; lung, n=3 and 4 for 0 and 9 mM, respectively).
Found at: doi:10.1371/journal.pbio.1000559.s002 (0.24 MB PDF)
Figure S3 Binding of protein kinases to longdaysin.
Affinity chromatography was performed as described in Figure 2C.
Proteins bound to compound 3 were subjected to Western blotting
with specific antibodies [anti-CKId (Santa Cruz Biotechnology, sc-
55553), anti-CKIa (Cell Signaling Technology, 2655), anti-
ERK1/2 (Cell Signaling Technology, 9102), and anti-CDK7
(Santa Cruz Biotechnology, sc-529)]. Anti-CKIa reacted with
short (close arrowhead) and long (open arrowhead) variants of
CKIa. Note that ERK1, a homolog of ERK2, showed less binding
to compound 3, indicating the selectivity of the compound.
Found at: doi:10.1371/journal.pbio.1000559.s003 (0.45 MB PDF)
Figure S4 Effects of siRNAs against longdaysin-binding
proteins on the circadian period. Data are extracted from
the primary screen of our genome-wide RNAi study [33].
Luminescence rhythms of Bmal1-dLuc U2OS cells were monitored
after transient transfection with siRNAs. Four independent
siRNAs were tested per gene as two siRNA pools (#1 and #2),
each containing two independent siRNAs. Data are the mean with
variation (n=2). Asterisk indicates low amplitude rhythm, which
sometimes causes wrong period estimation because of poor curve
fitting. Pairs #1 and #2 for H2AFV and pair #1 for H2AFZ have
highly possible off-target genes, and the result is not shown.
Found at: doi:10.1371/journal.pbio.1000559.s004 (0.23 MB PDF)
Figure S5 Comparison of the effect of individual siRNA
on the circadian period and the target gene expression.
Target gene knockdown effect from Figure 3Cii (x-axis in log scale; the
mean with variation, n=2) was plotted against period effect from
Figure 3Ci (y-axis; the mean with SEM, n=5–6) for each siRNA.
Found at: doi:10.1371/journal.pbio.1000559.s005 (0.24 MB PDF)
Figure S6 Interaction of CKIa and ERK2 with the clock
proteins. (A) Long exposure images of Figure 4A. (B) Interaction
of CKIa and ERK2 with PER1/2. (C) Interaction of CKIa,
CKId, and CKIe with PER1/2. HA-tagged kinases were co-
expressed with Flag-tagged clock proteins in HEK293T cells and
subjected to immunoprecipitation assay with anti-HA antibody.
Found at: doi:10.1371/journal.pbio.1000559.s006 (1.35 MB PDF)
Figure S7 Effect of longdaysin on CKIa- and CKId-
dependent phosphorylation of PER1. (A) HEK293T cell
extract expressing PER1 and CKIa was treated with l protein
phosphatase in the absence or presence of phosphatase inhibitor
and analyzed by Western blot. (B and C) PER1 was co-expressed
with CKIa or CKId in HEK293T cells. The cells were treated
with longdaysin (10 mM in B and 20 mM in C) or DMSO for 24 h
and analyzed by Western blot. Intensity profile of each PER1
band is shown in (B) and bottom panels of (C) by setting the peak
value as 1. Western blot image for (B) is shown in Figure 4C.
Arrows indicate (sub)peaks of PER1, which appeared depending
on CKIa or CKId and shifted by longdaysin treatment.
Found at: doi:10.1371/journal.pbio.1000559.s007 (0.56 MB PDF)
Figure S8 Effect of longdaysin on CKIa- and CKId-
dependent regulation of PER1 and PER2 stability. (A)
Flag-tagged PER1 was co-expressed with CKIa or CKId in
HEK293T cells. The cells were treated with 0, 10, or 20 mM
longdaysin for 24 h and then treated with cycloheximide from
time 0. The cells were collected 0, 2, 4, or 6 h later and analyzed
by Western blot. Note that co-expression of CKIa or CKId
accelerated degradation of PER1 compared with empty vector
control (upper panels, 0 mM longdaysin). The effects of CKIa and
CKId were partially inhibited by 10 mM longdaysin (middle
panels) and strongly inhibited by 20 mM longdaysin (lower panels).
(B) PER1-LUC, PER2-LUC, or LUC was co-expressed with
various amounts of GFP, CKIa, CKIa (KR), or CKId in
HEK293T cells. The cells were treated with cycloheximide from
time 0, and luminescence was recorded. The relative half-life of
PER1-LUC (upper panel) or PER2-LUC (lower panel) against
LUC is indicated. Data are the mean with SEM (n=4). Note that
CKIa did not affect PER2-LUC stability, while its effect on PER1-
LUC was saturated at 80 ng condition. (C) PER2-LUC or LUC
was co-expressed with GFP, CKIa, or CKId in HEK293T cells.
The cells were treated with 0 to 20 mM longdaysin for 24 h and
then treated with cycloheximide for luminescence recording. The
relative half-life of PER2-LUC against LUC is indicated. Data are
the mean with SEM (n=4).
Found at: doi:10.1371/journal.pbio.1000559.s008 (0.96 MB PDF)
Figure S9 Effect of longdaysin on body length of
zebrafish. Zebrafish were treated with longdaysin for luminescence
recording (Figure 5). Body length of zebrafish was measured after the
1 wk treatment and plotted against compound concentration (n=13,
5, 11, and 8 for 0, 1, 3, and 9 mM longdaysin, respectively).
Found at: doi:10.1371/journal.pbio.1000559.s009 (0.21 MB PDF)
Figure S10 Effects of CKI inhibitors D4476 and IC261
on the circadian period. Luminescence rhythms of Bmal1-dLuc
U2OS cells were monitored in the presence of various concen-
trations of compounds. Data are the mean with SEM (n=4).
Longdaysin and D4476 showed cytotoxicity at 71 mM.
Found at: doi:10.1371/journal.pbio.1000559.s010 (0.23 MB PDF)
Table S1 siRNA sequences.
Found at: doi:10.1371/journal.pbio.1000559.s011 (0.22 MB PDF)
Table S2 qPCR primer sequences.
Found at: doi:10.1371/journal.pbio.1000559.s012 (0.24 MB PDF)
Text S1 Supporting methods. Synthesis of compound 1,
Longdaysin, compound 2, and compound 3.
Found at: doi:10.1371/journal.pbio.1000559.s013 (0.49MBDOC)
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